Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.
about
A Review of Modeling Approaches to Predict Drug Response in Clinical OncologyPopulation pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjectsComparative performance of cell life span and cell transit models for describing erythropoietic drug effectsPopulation pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy.Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.Lifespan based indirect response models.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model.Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy.Optimal designs for composed models in pharmacokinetic-pharmacodynamic experimentsQuantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.Population pharmacokinetics and exposure-response of albinterferon alfa-2b.Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.Confirmatory analysis for phase III population pharmacokinetics.Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins
P2860
Q28066777-3AF93000-D96F-4547-B87E-7C60ADE778B3Q34953673-EEDC0E4C-0C7F-4434-9C0A-36FAFC020480Q35132886-57DDEAE9-F1F9-4A19-9026-A2B5C85854B6Q35595803-CD62484F-8356-4AE3-97E4-A84D2F05D93FQ36087965-CB200E28-C014-4B3C-B955-142947B23B72Q36121654-BD8D7AEE-658C-451E-B865-4EF3A9CD9046Q36354544-90244E9D-4828-414B-A8AA-5827905BBF1BQ37161497-3E19F824-54A3-48E1-A3DB-94D97D396DF7Q37972792-FF4856FD-4EF4-4EE9-BA77-0D2085EA1D9CQ38126361-FE500E63-5850-4249-932D-348A36CB184AQ38241696-0218D270-A7CE-47F7-8FF5-D2843F6A8A1CQ38281535-18EB9437-3EAE-491B-BC45-F7A5A47132AEQ38289581-AB41EEEA-2F13-45FF-8902-588B4D60FCDFQ41021058-491AC778-C398-4184-8CEA-6C1590650079Q41529847-E8A67AF7-15FC-4871-ABE6-B1689608A21BQ42013526-203745F1-BFE0-4769-B6A4-0FDCD342BC32Q42945852-87E5BA5E-54D7-4019-9792-61D49798E3A3Q43036580-EBF02331-1ABE-4EC0-93AC-1E827F721C25Q45231648-2DD4DA8A-7F0C-4A91-B329-10F30176EED6Q45347575-1171095C-16BD-4B2D-B3E5-2674D8D57338Q46028013-9D3A5E61-9131-4F25-94BE-9556BE63BFA2Q46383671-8FDC4840-C36B-4DC4-AE07-6632A9D2B749Q58869607-60DECD87-BB47-469D-BD07-B2F7D8F62C04
P2860
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development and evaluation of ...... going multicycle chemotherapy.
@en
Development and evaluation of ...... going multicycle chemotherapy.
@nl
type
label
Development and evaluation of ...... going multicycle chemotherapy.
@en
Development and evaluation of ...... going multicycle chemotherapy.
@nl
prefLabel
Development and evaluation of ...... going multicycle chemotherapy.
@en
Development and evaluation of ...... going multicycle chemotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Development and evaluation of ...... going multicycle chemotherapy.
@en
P2093
Anne C Heatherington
Balaji Agoram
Marc R Gastonguay
P2860
P2888
P304
P356
10.1208/AAPSJ080364
P407
P577
2006-09-01T00:00:00Z
P5875
P6179
1018042396